Calidi Biotherapeutics, Inc. (CLDI): Results of Operations and Financial Condition
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a firs
How this was made
The 30-second read
Why it matters
The most tradable new information is the FDA’s positive pre-IND feedback and agreement on key CMC and non-clinical elements for the proposed first-in-human study, paired with a stated first patient dosing target in Q1 2027. Financially, the company reports a net loss and a reduced cash balance versus year-end, which can increase financing sensitivity.
Market read
Traders can reprice CLDI’s regulatory risk for CLD-401 based on the disclosed FDA pre-IND outcome, while also monitoring cash runway and dilution risk.
What to watch
The reverse split (1-for-16) and the magnitude of cash burn versus runway are not quantified beyond cash balances, which can materially affect trading despite regulatory progress.
Background
This SEC 8-K (Item 2.02) reports Q2 2026 financial results and highlights, including an FDA pre-IND interaction for CLD-401 and new preclinical data for CLD-501 at ASCO.
Ticker impact
Calidi says FDA provided positive pre-IND feedback for CLD-401 and agreed on CMC and the first-in-human study design for Q1 2027 dosing.
Likely positive bias for CLDI shares, with follow-through dependent on cash runway and subsequent IND/Phase 1 execution milestones.
The filing discloses a specific FDA pre-IND (Type B) outcome and a planned first patient dosing window (Q1 2027), which are actionable catalysts for biotech development-stage risk.
Market effects
Reinforces investor focus on in situ T-cell engager platforms and FDA pre-IND de-risking as a valuation driver in oncology biotech.
Limited, primarily affects US small-cap biotech sentiment.
Low, as the disclosure is company-specific and US FDA process related.
Counterpoint
Despite positive pre-IND feedback, the company still reports low cash ($4.1m) and ongoing losses, so dilution or financing risk may dominate near-term price action.
Key entities
- issuerCalidi Biotherapeutics, Inc.
NYSE American-listed biotech reporting Q2 2026 results and FDA pre-IND feedback for CLD-401.
- drug_candidateCLD-401
Lead RedTail platform virotherapy; FDA pre-IND (Type B) feedback supports first-in-human study design.
- drug_candidateCLD-501
In situ T-cell engager approach presented with new ASCO 2026 preclinical data.
- regulatorU.S. FDA
Provided positive pre-IND feedback and agreed on CMC and non-clinical program aspects.
